翰宇药业：拟向特定对象增发募资不超过人民币9.68亿元

Core Viewpoint - Han Yu Pharmaceutical announced the approval of a private placement of A-shares, aiming to raise up to RMB 968 million for various projects, while cautioning investors about potential uncertainties in the process [1] Summary by Categories Fundraising Details - The private placement will involve no more than 35 specific investors [1] - The issuance price will be no less than 80% of the average trading price of the company's stock over the 20 trading days prior to the pricing date [1] - The total amount to be raised is up to RMB 968 million [1] Allocation of Funds - The funds will be allocated to several projects: - Peptide drug production line and green intelligent expansion project: Total investment of approximately RMB 549 million, with RMB 495 million from the raised funds [1] - Peptide fragment expansion construction project: Total investment of RMB 45.8 million, with RMB 40 million from the raised funds [1] - R&D laboratory upgrade project: Total investment of RMB 57.75 million, with RMB 55 million from the raised funds [1] - Semaglutide R&D project: Total investment of approximately RMB 133 million, with RMB 98 million from the raised funds [1] - Semaglutide domestic injection (for diabetes indication) project: Total investment of RMB 57 million, with RMB 25 million from the raised funds [1] - Semaglutide oral tablet (for diabetes indication) project for the U.S. market: Total investment of RMB 75.8 million, with RMB 73 million from the raised funds [1]